What is Repare Therapeutics?
Repare Therapeutics is a clinical-stage biotechnology firm at the forefront of precision oncology. The company distinguishes itself through the application of its proprietary SNIPRx platform, a genome-wide, CRISPR-enabled discovery engine designed to identify synthetic lethality targets. By focusing on genomic instability and DNA damage repair, Repare Therapeutics aims to develop highly targeted, effective cancer therapies that address specific molecular vulnerabilities in tumor cells.
The company's market position is bolstered by its ability to integrate advanced computational biology with rigorous clinical validation. This dual-pronged approach allows for the rapid identification of novel therapeutic candidates, effectively shortening the discovery cycle and enhancing the probability of clinical success. As the firm matures, its focus remains on translating complex genetic data into actionable, life-saving interventions for oncology patients globally.
How much funding has Repare Therapeutics raised?
Repare Therapeutics has raised a total of $150.5M across 2 funding rounds:
Series A
$68M
Series B
$82.5M
Series A (2017): $68M with participation from Fonds de solidaritu00e9 FTQ, MPM Capital, Celgene Switzerland, and Versant Ventures
Series B (2019): $82.5M led by MPM Capital, Versant Ventures, BVF Partners L.P, Logos Capital, BDC Capital, OrbiMed, Redmile, Fonds de solidarité FTQ, and Cowen Healthcare Investments
Key Investors in Repare Therapeutics
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies around the world, leveraging extensive backgrounds in venture capital and scientific research.
MPM Capital
MPM BioImpact manages early-stage venture funds and private/public impact funds, focusing on converting cutting-edge science into therapeutics for patients in need.
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals and medical devices with a deep understanding of healthcare innovation cycles.
What's next for Repare Therapeutics?
Looking ahead, the strategic deployment of the $82.5M will likely focus on the advancement of the company's lead clinical programs and the expansion of its internal R&D pipeline. With a robust balance sheet, Repare Therapeutics is well-positioned to accelerate its clinical trial milestones and potentially explore strategic partnerships that could further validate its SNIPRx platform. The company's roadmap emphasizes the transition from discovery-stage innovation to late-stage clinical development, a critical phase that will determine its long-term commercial viability and impact on the oncology market. Investors will be closely monitoring the firm's ability to maintain its scientific edge while navigating the regulatory and operational challenges inherent in bringing precision medicines to market.
See full Repare Therapeutics company page
